NORTHWEST BIOTHERAPEUTICS INC (NWBO)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Research and other | 131 | 375 | 357 | 510 |
| Research and development | 7,430 | 8,351 | 8,130 | 8,293 |
| General and administrative | 7,480 | 9,335 | 7,028 | 9,681 |
| Total operating costs and expenses | 14,910 | 17,686 | 15,158 | 17,974 |
| Loss from operations | -14,779 | -17,311 | -14,801 | -17,464 |
| Interest expense | 1,826 | 1,602 | 2,080 | 1,681 |
| Loss from extinguishment of debt | -4,516 | -7,282 | -6,820 | -914 |
| Foreign currency transaction gain (loss) | 3,640 | 1,898 | 2,760 | -45 |
| Change in fair value of derivative liabilities | 724 | 1,280 | -1,590 | 2,409 |
| Change in fair value of share payable | -240 | -23 | 70 | 67 |
| Change in fair value of convertible notes | 2,392 | 3,697 | 3,087 | -241 |
| Loss from issuance of debt | -773 | - | - | - |
| Total other expense | -599 | -2,032 | -4,573 | -405 |
| Net loss | -15,378 | -19,343 | -19,374 | -17,869 |
| Deemed dividend related to warrant modifications | 560 | 265 | 132 | 441 |
| Net loss attributable to common stockholders | -15,938 | -19,608 | -19,506 | -18,310 |
| Foreign currency translation adjustment | 3,248 | 1,644 | - | - |
| Total comprehensive loss | -19,186 | -21,252 | -19,506 | -18,310 |
| Earnings per share, basic | -0.01 | -0.01 | -0.02 | -0.02 |
| Earnings per share, diluted | -0.01 | -0.01 | -0.02 | -0.02 |
| Weighted average number of shares outstanding, basic | 1,438,198 | 1,359,496 | 1,258,532 | 1,214,316 |
| Weighted average number of shares outstanding, diluted | 1,438,198 | 1,359,496 | 1,258,532 | 1,214,316 |